Cardax Inc. (CDXI)

Market Cap	802,516
Revenue (ttm)	500,710
Net Income (ttm)	-5.43M
Shares Out	802,516
EPS (ttm)	-7.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	215
Open	0.89
Previous Close	1.00
Day's Range	1.00 - 1.10
52-Week Range	0.05 - 6.00
Beta	1.02
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About CDXI

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a targ...

• Industry: Pharmaceuticals
• Employees: 10
• Stock Exchange: OTCMKTS
• Ticker Symbol: CDXI

Full Company Profile

News

There is no news available yet.